As in the updated European Crohn’s and Colitis Organisation (ECCO) recommendations, anti-TNF agents may be used on the basis of multidisciplinary decisions involving oncologists, taking into consideration current and recent IBD activity and alternative treatment options [53]. Here, TNF is linked to inflammatory bowel disease.